Clinical Trials Logo

Clinical Trial Summary

The molecular mechanisms involved in venous endothelial dysfunction are largely unknowns. Autophagy is an intracellular mechanism devoted to the removal of damaged cytoplasmic elements. Previous evidence demonstrated that activation of autophagy exerts beneficial effects in the cardiovascular system, reducing cardiac damage and improving cardiac function in response to stress. However, the association between venous endothelial dysfunction and autophagy remains to be characterized. In this study the investigators will test whether reactivation of autophagy through a natural compound (spermidine) is able to improve vascular function in saphenous veins derived from patients subjected to saphenectomy. The same outcome will be evaluated in saphenous veins isolated from patients with atherosclerotic obstructive disease of the lower limbs subjected revascularization through implantation of venous by-pass.


Clinical Trial Description

Endothelial dysfunction contributes to different cardiovascular diseases, such as atherosclerosis, myocardial infarction, stroke and peripheral artery diseases. Recent evidence also demonstrated that endothelial dysfunction is associated with vascular venous diseases. In this regard, venous endothelial dysfunction contributes to the development of varicose veins and deep vein thrombosis. Disequilibrium in endothelial function is also present in venous traits derived from saphenous veins which are routinely used as aortocoronary by-pass. The molecular mechanisms involved in venous diseases require further investigations. Autophagy, the intracellular mechanism devoted to the removal of dysfunctional or senescent cytoplasmic elements may represent a new therapeutic target for the treatment of vascular diseases. In this regard, it has been demonstrated that the enhancement of autophagy limits cardiac injury in pre-clinical models of cardiovascular diseases. However, the association between autophagy and vascular disease is still unknown in humans. Spermidine is a natural activator of autophagy which has been demonstrated to extend lifespan in mice and to reduce cardiac dysfunction through autophagy-dependent mechanisms. The objectives of this study will be the following: 1) to test whether spermidine is able to improve vascular function and to reduce oxidative stress in saphenous veins obtained from patients subjected to saphenectomy due to chronic venous insufficiency or varicose veins; 2) to test whether spermidine is able to improve vascular function in saphenous veins derived from patients with atherosclerotic obstructive disease of lower limbs subjected to revascularization through implantation of arteriosus by-pass. In a different set of experiments, the investigators will also test whether vein portions incubated with spermidine show increased autophagy and decreased markers of oxidative stress with respect to controls. The investigators expect that venous segments treated with spermidine will show an amelioration of endothelial function ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04138134
Study type Observational
Source Neuromed IRCCS
Contact
Status Active, not recruiting
Phase
Start date February 1, 2022
Completion date April 1, 2023

See also
  Status Clinical Trial Phase
Recruiting NCT05633277 - Outcomes of Sclerotherapy of the Ulcer Bed Compared to a Combination of Ablation and Injections N/A
Completed NCT04758728 - Adrenaline Reduces Ecchymoses and Hematomas and Improves Quality of Life After Classic Saphenous Vein Stripping N/A
Recruiting NCT05409976 - The GORE® VIAFORT Vascular Stent IVC Study N/A
Completed NCT06395025 - Blinded User Study for the Evaluation of the Acceptability and Efficacy of One Medical Device in Venous Return in Comparison With a Control Group N/A
Not yet recruiting NCT04358497 - Endovascular Versus Medical Treatment for the Pelvic Congestion Syndrome Phase 4
Completed NCT03703765 - Volume Estimation of the Limb After VEnous Treatment N/A
Completed NCT01368159 - Efficacy on Pain Following a Procedure for Injecting Sclerotherapeutic Foam Into the Great Saphenous Vein Phase 4
Recruiting NCT05628948 - Vascular Lab Resource (VLR) Biorepository
Completed NCT06153680 - Consumer Study for the Evaluation of the Usability and Efficacy of One Medical Device in Venous Return N/A
Terminated NCT03363633 - Perforator Vein Injection for Symptomatic Venous Disease N/A
Recruiting NCT05489588 - The GORE® VIAFORT Vascular Stent Iliofemoral Study N/A
Not yet recruiting NCT06433024 - Training of a Artificial Intelligence Model to Detect Venous Diseases Using PPG Technology
Completed NCT02655887 - BARD® The VENOVO™ Venous Stent Study for Treatment of Iliofemoral Occlusive Disease N/A
Recruiting NCT05050799 - US Post-Market Surveillance Study of the Surfacer System
Completed NCT01993914 - Prevalence of MTHFR Polymorphisms in Venous Disease N/A
Terminated NCT04964817 - HFpEF and Symptomatic Obstructive Iliofemoral Venous Disease Study
Recruiting NCT02139085 - Great Saphenous Vein Electrocoagulation Phase 2
Completed NCT01509599 - Cooling Lower Leg Skin to Prevent Venous Leg Ulcers in Patients With Poor Vein Circulation Phase 1/Phase 2
Terminated NCT03630185 - A Comparison of Custom-manufactured vs. Off-the-rack (OTR) Compression Hosiery for Initial Management of Venous Disease N/A